Off-Label Pacira Warning Letter Dropped From FDA's Website
This article was originally published in The Gray Sheet
Executive Summary
FDA has apparently taken down a warning letter from its website describing off-label marketing violations by Pacira Pharmaceuticals, a drug company that is suing the agency over First Amendment free speech rights. The agency’s response in the lawsuit is due this month.
You may also be interested in...
Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.